KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

NovoCure (NVCR) EPS (Weighted Average and Diluted) (2018 - 2026)

NovoCure's EPS (Weighted Average and Diluted) history spans 9 years, with the latest figure at -$0.62 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 100.0% to -$0.62 in Q1 2026 year-over-year; TTM through Mar 2026 was -$1.53, a 1.32% decrease, with the full-year FY2025 number at -$1.22, up 21.79% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.62 in Q1 2026 for NovoCure, down from -$0.22 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for NVCR hit a ceiling of -$0.04 in Q1 2022 and a floor of -$0.62 in Q1 2026.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.37 across 5 years, with a median of -$0.36 in 2022.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 1150.0% in 2023 and later skyrocketed 63.93% in 2025.
  • Tracing NVCR's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.36 in 2022, then fell by 22.22% to -$0.44 in 2023, then plummeted by 38.64% to -$0.61 in 2024, then soared by 63.93% to -$0.22 in 2025, then plummeted by 181.82% to -$0.62 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for NVCR at -$0.62 in Q1 2026, -$0.22 in Q4 2025, and -$0.33 in Q3 2025.